Abstract: Objective To evaluate the efficacy of Chinese patent medicines related to Trollius chinensis (Trollius granules, Trollius tablets) as against other drugs (ribavirin, Fufang Caoshanhu Hanpian) in the treatment of upper respiratory tract infections. Methods Related literature was searched for and collected from PubMed, Cochrane Library, CBM, CNKI, VIP and Wangfang database from inception to August 30, 2020 with Trollius chinensis and upper respiratory tract infection as the keywords. Literature was screened and data was extracted according to the inclusion and exclusion criteria. RevMan5.3 software was used for assessment of the risk of bias of the included studies and for data analysis. Results Seven randomized controlled trials were included involving 1 178 patients totally. The result of Meta analysis showed that the total effective rates of experimental groups (Trollius granules and Trollius tablets) against upper respiratory tract infections were higher than those of the control groups(ribavirin and Fufang Caoshanhu Hanpian) respectively. Conclusions uch patent Chinese medicines as Trollius granules and Trollius tablets have better clinical efficacy against upper respiratory tract infections than other drugs and clinical application could be considered. However, the samples of the included studies are not enough and the included studies have a higher risk of bias. This conclusion needs to be further verified by more high-quality, multi-center, large-sample random experiments.

Key words: Trolliius chinensis, upper respiratory tract infection, Meta analysis